Print this Article
RSSBusiness Wire
New Customer and Sales Associates Totaled 8,751 vs. 6,522 in July
AMS Health Sciences, Inc. (AMEX:AMM) (AMS), announced August month-end results of its new customer acquisition program, totaling 8,751 new associates and preferred customers, averaging $60 per monthly recurring order. New sales associate autoships totaled 735, and customer acquisition autoships totaled 8,016.
Since launching the new customer acquisition campaign on March 6, 2004, new sales associates and preferred customers have been added as follows: 3,516 in March; 3,732 in April; 4,778 in May; 5,143 in June; 6,522 in July and 8,751 in August. These compare favorably to fiscal year 2003 additions of 979 in March; 997 in April; 1,005 in May; 969 in June; 1,147 in July and 1,318 in August. Total sales for August were approximately $1,485,000, an increase of approximately 3.1% over the prior month.
"Execution is the focus of management with revenue up three consecutive months, recruiting increasing six months, Free Trial preferred customer acquisitions at over 8,000 and total drafted monthly recurring product orders in excess of 17,000," said AMS President David D'Arcangelo. "September is the month we have been working toward as we prepare to launch our Energy/Anti-fatigue weight loss product during mid-month, supported by a broad based marketing effort across many marketing channels, including Infomercial testing, telemarketing, Internet, events and traditional sales. We look to September 15 as the launch of the new AMS Health Sciences Inc. We will continue to aggressively execute our business model."
About AMS Health Sciences, Inc.
AMS Health Sciences, Inc., sells more than 60 natural nutritional supplements, weight management products, and natural skincare products, including the world's number-one all-natural weight loss and stress reliever, Prime One, through independent distributors across the U.S. and Canada. More information about the Company is available at http://www.amsonline.com.
Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Certain, but not necessarily all, of such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipates," "believes," "expects," "may," "will," or "should" or other variations thereon, or by discussions of strategies that involve risks and uncertainties. The actual results of the Company or industry results may be materially different from any future results expressed or implied by such forward-looking statements.